Ekso Bionics Holdings Management

Management criteria checks 2/4

Ekso Bionics Holdings' CEO is Scott Davis, appointed in Dec 2022, has a tenure of 1.42 years. total yearly compensation is $637.02K, comprised of 58.9% salary and 41.1% bonuses, including company stock and options. directly owns 0.51% of the company’s shares, worth $116.92K. The average tenure of the management team and the board of directors is 2.3 years and 2.9 years respectively.

Key information

Scott Davis

Chief executive officer

US$637.0k

Total compensation

CEO salary percentage	58.9%
CEO tenure	1.4yrs
CEO ownership	0.5%
Management average tenure	2.3yrs
Board average tenure	2.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Scott Davis's remuneration changed compared to Ekso Bionics Holdings's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$4m
Dec 31 2023	US$637k	US$375k	-US$15m
Sep 30 2023	n/a	n/a	-US$15m
Jun 30 2023	n/a	n/a	-US$16m
Mar 31 2023	n/a	n/a	-US$15m
Dec 31 2022	US$1m	US$370k	-US$15m

Compensation vs Market: Scott's total compensation ($USD637.02K) is above average for companies of similar size in the UK market ($USD347.32K).

Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.

CEO

Scott Davis (52 yo)

1.4yrs

Tenure

US$637,020

Compensation

Mr. Scott G. Davis serves as Chief Executive Officer of Ekso Bionics Holdings, Inc. since December 04, 2022 and serves as Director since December 08, 2022, and also served as its President & Chief Operatin...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Scott Davis	CEO & Director	1.4yrs	US$637.02k	0.51% $ 116.9k
Jerome Wong	Corporate Controller	7yrs	US$726.08k	0.62% $ 142.7k
Jason Jones	Chief Operating Officer	1.3yrs	US$710.24k	1.09% $ 251.0k
Rachael Anderson	Global Director of Marketing & Strategic Growth	3.3yrs	no data	no data
Ann Cookson	Human Resources Director	2.1yrs	no data	no data
Foon Chwee	President of APAC	6.3yrs	no data	no data
Stephan Aderhold	Senior VP & GM of EMEA	2.3yrs	no data	no data

2.3yrs

Average Tenure

Experienced Management: 0IFR's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Scott Davis	CEO & Director	1.4yrs	US$637.02k	0.51% $ 116.9k
Sherri Medina	Member of Advisory Council	no data	no data	no data
Hans Keirstead	Member of Advisory Council	no data	no data	no data
Mary Cloyd	Independent Director	3.4yrs	US$147.01k	0.41% $ 95.5k
Corinna Lathan	Lead Independent Director	2.4yrs	US$158.13k	0.45% $ 102.8k
Nancy Byl	Member of Advisory Council	no data	no data	no data
Tom Kelley	Member of Advisory Council	no data	no data	no data
Daniel Kraft	Member of Advisory Council	no data	US$72.21k	no data
Kel Bergmann	Member of Advisory Council	no data	no data	no data
Graham Creasey	Member of Advisory Council	no data	no data	no data
Suzy Kim	Member of Advisory Council	no data	no data	no data
Rhonda Wallen	Independent Director	3.4yrs	US$142.33k	0.41% $ 95.5k

2.9yrs

Average Tenure

55yo

Average Age

Experienced Board: 0IFR's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Ekso Bionics Holdings Management

Management criteria checks 2/4

Key information

Recent management updates

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024

High number of new and inexperienced directors

Executive Chairman of the Board recently sold US$66k worth of stock

High number of new and inexperienced directors

High number of new and inexperienced directors

Ekso Bionics Holdings, Inc Announces Director Changes

Recent updates

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.33 loss in 1Q 2023)

Forecast to breakeven in 2026

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024

Ekso Bionics Holdings, Inc. to Report Q1, 2024 Results on Apr 29, 2024

No longer forecast to breakeven

Full year 2023 earnings released: US$1.10 loss per share (vs US$1.16 loss in FY 2022)

Ekso Bionics Holdings, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Forecast to breakeven in 2026

Ekso Bionics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. Launches GaitCoach Software for EksoNR

Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Ekso Bionics Holdings, Inc. Receives CMS Coding Approval for Ekso Indego Personal

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.33 loss in 3Q 2022)

Ekso Bionics Holdings, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Ekso Bionics Holdings, Inc. Receives Non-Compliance Notice from Nasdaq

New major risk - Financial position

Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.23 loss in 2Q 2022)

Ekso Bionics Holdings, Inc. to Report Q2, 2023 Results on Jul 27, 2023

High number of new and inexperienced directors

Executive Chairman of the Board recently sold US$66k worth of stock

High number of new and inexperienced directors

High number of new and inexperienced directors

No longer forecast to breakeven

Full year 2022 earnings released: US$1.16 loss per share (vs US$0.80 loss in FY 2021)

Forecast to breakeven in 2025

Ekso Bionics Holdings, Inc Announces Director Changes

Ekso Bionics Holdings, Inc. acquired Human Motion and Control Business Unit of Parker Hannifin Corporation for $10 million.

Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer

Ekso Bionics Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.10 loss in 2Q 2021)

Ekso Bionics Holdings, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Ekso Bionics Holdings, Inc. Receives FDA Clearance to Market Its Eksonr(Tm) Robotic Exoskeleton for Use with Multiple Sclerosis Patients

Ekso Bionics Holdings, Inc. Announces Chief Financial Officer Changes

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 09, 2022

Ekso Bionics Holdings, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Ekso Bionics Holdings, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.30 profit in 3Q 2020)

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$1.88 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.44 loss in 1Q 2020)

Full year 2020 earnings released: US$2.21 loss per share (vs US$2.53 loss in FY 2019)

Revenue misses expectations

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 10, 2021

Ekso Bionics Holdings, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Ekso Bionics Holdings, Inc. Announces Resignation of Ted Wang as Member of the Board of Director

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age